Clinical Trials
2 trialsNCT03404726 2022-01-11
A Study to Investigate BAY2402234, a Dihydroorotate Dehydrogenase (DHODH) Inhibitor, in Myeloid Malignancies
Bayer
Phase 1 Terminated
NCT05061251 2022-01-11
Surgical Window of Opportunity Study of Orally Administered BAY 2402234 in Recurrent Glioma
University of Texas Southwestern Medical Center
Phase EARLY_PHASE1 Withdrawn